The CGTLive™ Oncology specialty topic page highlights the latest clinical care news related to the development of cell therapies, gene therapies, and engineered and regenerative medicines for various cancers. It also houses video interviews with key opinion leaders in the field of oncology speaking to the related FDA actions, clinical guideline updates, and clinical trial findings in the field of gene and cell therapy for oncologic diseases.
May 11th 2024
All 139 tumors screened had enhanced expression of CCNG1, a seldom-recorded gene on NGS.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Maintenance Ixazomib Extends PFS in Newly Diagnosed Multiple Myeloma
December 3rd 2018Two-year maintenance therapy with ixazomib led to a 39% improvement in progression-free survival compared with placebo in patients with newly diagnosed multiple myeloma who achieved a partial response to induction treatment with a proteasome inhibitor and/or an immunomodulatory agent following autologous stem cell transplant.
Tisagenlecleucel OS, RFS Sustained in Long-Term Follow-Up for Pediatric ALL
December 2nd 2018Treatment with the CD19-targeted CAR T-cell therapy tisagenlecleucel demonstrated sustained rates of relapse-free survival and overall survival at 24 and 18 months for pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia.
Dr Brian Koffman Outlines the Follow-up as a Patient Treated With CAR T
November 24th 2018After being treated for his chronic lymphocytic leukemia with chimeric antigen receptor (CAR) T-cell therapy, Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society, is being followed for 15 years to better understand if there are any undiscovered adverse events that pop up and how durable the response is.
Dr. Pinilla-Ibarz on the FDA Approval of Moxetumomab Pasudotox in Hairy Cell Leukemia
September 13th 2018Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the FDA approval of moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.
Shain Shares Strategies in Newly Diagnosed Myeloma
September 13th 2018Kenneth H. Shain, MD, PhD, discusses the evolution of treatment for patients with newly diagnosed multiple myeloma and how physicians are leveraging data with chimeric antigen receptor T-cell therapy and minimal residual disease negativity to improve outcomes.
Dr. Locke Discusses Unanswered Questions With CAR T-Cell Therapy
September 5th 2018Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses unanswered questions with chimeric antigen receptor T-cell therapy.
This Week in Managed Care: August 24, 2018
August 24th 2018This week, the top managed care news included a panel mostly endorsed the use of patient-reported outcomes for coverage of chimeric antigen receptor T-cell therapy; the US Preventive Services Task Force released new recommendations for cervical cancer screening; research found accountable care organization penetration may be changing how physicians work.
First Targeted Therapy Approved for R/R AML With IDH1 Mutation
July 22nd 2018The FDA approved the first targeted therapy for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. In addition, FDA also approved a companion diagnostic to be used to detect the specific mutations in the IDH1 gene.
AbbVie and Calibr to Collaborate on CAR T-Cell Development
June 29th 2018Drug manufacturer AbbVie, and a nonprofit drug discovery division of Scripps Research, Calibr, announced earlier this week that they are partnering to develop chimeric antigen receptor (CAR-T) cell therapies primarily aimed at treating cancer, particularly, solid tumors.
CD22 CAR T-cell Therapy Effective After CD19 CAR Therapy Failure in Children With B-ALL
June 16th 2018A CAR T-cell therapy specific for CD22 was safe and provided high response rates for pediatric patients with B-cell acute lymphoblastic leukemia who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment.
Dr. Costa on Triplet of Venetoclax, Carfilzomib, and Dexamethasone in Multiple Myeloma
June 3rd 2018Luciano J. Costa, MD, PhD, associate professor of medicine, Blood and Marrow Transplantation and Cell Therapy Program, University of Alabama at Birmingham School of Medicine, discusses phase II findings with the triplet regimen of venetoclax (Venclexta), carfilzomib (Kyprolis), and dexamethasone in patients with relapsed/refractory multiple myeloma. Costa shared this insight in an interview with OncLive during the 2018 ASCO Annual Meeting.
FDA Grants Crizotinib Breakthrough Designation for MET+ NSCLC and ALK+ ALCL
May 30th 2018The FDA has granted crizotinib a breakthrough therapy designation for the treatment of patients with metastatic non–small cell lung cancer with MET exon 14 alterations, and for use in patients with relapsed/refractory ALK+ anaplastic large cell lymphoma.
FDA Approves CAR T-Cell Treatment Kymriah for Adult B-Cell Lymphoma
May 2nd 2018Tisagenlecleucel, sold as Kymriah, has gained its second indication following the FDA's approval of the chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, the most common form of non-Hodgkin lymphoma.
Gene Therapy in Community Practices—Administering CAR T Therapies
April 13th 2018How are community practices coping with administering chimeric antigen receptor (CAR)-T treatments? At the 2018 Community Oncology Conference hosted by the Community Oncology Alliance, Houston Holmes, MD, MBA, FACP, Texas Oncology, shared his experience with administering CAR T-cells in a community cancer center–based setting.
What We're Reading: 2018 ACA Enrollment; Spread of Rare Superbug; Off-the-Shelf CAR T Therapies
April 4th 2018Enrollment for 2018 in Affordable Care Act plans is only slightly below figures from 2017; a rare breed of antibiotic-resistant bacteria is spreading in hospitals; a new company will develop off-the-shelf CAR T-cell therapies that do not need to be personalized to the patient.